The Prevalence of COPD in Patients With Cardiovascular Disease and the Benefit of Cardiopulmonary Co-management

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age40+
SponsorAstraZeneca

About this trial

This is a multi-center, prospective, and interventional study conducted in 3 types of cardiovascular diseases (CVD) participants , including 3 cohorts which are patients with newly or previously diagnosed coronary heart disease ( CHD), atrial fibrillation ( AF) and chronic heart failure (CHF).

Eligibility criteria

Qualifiers

Give signed written informed consent to participate.

At least 40 years of age at baseline visit.

Previous or newly diagnosed by at least one of the 3 types of CVD which are,

Coronary heart disease ( CHD )

Disqualifiers

Significant diseases or conditions, which, in the opinion of the investigator, may put the participant at risk because of participation in the study or may influence either the results of the study or the participant's ability to participate in the study.

Women who are pregnant or lactating or are planning to become pregnant, or women of childbearing potential who are not using an acceptable method of contraception.

Participant who are not able to provide written informed consent.

Treatment with investigational study drug or device in another clinical study within the last 30 days or five half lives prior to baseline visit , whichever is longer.

Trial design

Treatments tested in this trial

  • Guideline education and implementation intervention

Treatment groups

3,000 Participants
are divided into 1 treatment group

Sponsors and collaborators